Orphan drugs expenditure in the Netherlands in the period 2006–2012

Orphanet Journal of Rare Diseases

Leona Hakkaart¹  Adri Steenhoek¹  Tim A Kanters¹ 

[1] Institute for Medical Technology Assessment, Department of Health Policy & Management, Erasmus University Rotterdam, Burgemeester Oudlaan 50, Rotterdam, 3000DR, The Netherlands

关键词: Reimbursement;    Budget impact;    Uptake;    Orphan drugs;   

Others  :  1149682
DOI  :  10.1186/s13023-014-0154-0

 received in 2014-07-11, accepted in 2014-09-25,  发布年份 2014

【 摘 要 】

Background

The relatively low budget impact of orphan drugs is often used as an argument in reimbursement decisions. However, overall, the budget impact of orphan drugs can still be substantial. In this study, we assess the uptake and budget impact of orphan drugs in the Netherlands.

Methods

We examined the number of orphan drugs, the number of patients and budget impact of orphan drugs in the Netherlands in the period 2006 to 2012, both for inpatient and outpatient orphan drugs. Budget impact was provided in absolute numbers and relative to total pharmaceutical spending.

Results

The number of orphan drugs and patients treated increased substantially over the period studied. Overall, budget impact increased substantially over a period of six years, both in absolute terms (326% increase) as well as relative to total pharmaceutical spending (278% increase). Growth rates decreased over time. In 2012, 17% of available drugs had an individual budget impact of more than ¿10 million per year.

Conclusions

Individual budget impact of orphan drugs is often limited, although exceptions exist. However, in total, the budget impact of orphan drugs is considerable and has grown substantially over the years. This could potentially influence reimbursement decisions for orphan drugs in the future.

【 授权许可】

   
2014 Kanters et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Joppi R, Bertele¿ V, Garattini S: Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. Eur J Clin Pharmacol 2013, 69:1009-1024.
• [2]Burls A, Austin D, Moore D: Commissioning for rare diseases: View from the frontline. BMJ 2005, 331:1019-1021.
• [3]Sheldon T: Dutch doctors call for EU evaluation of cost effectiveness of high cost orphan drugs. BMJ 2012, 345:e5461.
• [4]Regulation (EC) no 141/2000 of the European parliament and of the council of 16 December 1999 on orphan medicinal products Offic J Eur Commun 2000, L18/1:1-5.
• [5]Hughes DA, Tunnage B, Yeo ST: Drugs for exceptionally rare diseases: Do they deserve special status for funding? QJM 2005, 98:829-836.
• [6]Cohen J, Stolk E, Niezen M: The increasingly complex fourth hurdle for pharmaceuticals. Pharmacoeconomics 2007, 25:727-734.
• [7]Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M, Orlewska E, Watkins J, Trueman P: Principles of good practice for budget impact analysis: Report of the ISPOR task force on good research practices¿budget impact analysis. Value Health 2007, 10:336-347.
• [8]Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S: Budget impact analysis of orphan drugs in Belgium: Estimates from 2008 to 2013. J Med Econ 2010, 13:295-301.
• [9]Orofino J, Soto J, Casado MA, Oyagüez I: Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007. Appl Health Econ Health Policy 2010, 8:301-315.
• [10]Schey C, Milanova T, Hutchings A: Estimating the budget impact of orphan medicines in Europe: 2010¿2020. Orphanet J Rare Dis 2011, 6:62. BioMed Central Full Text
• [11]Hutchings A, Schey C, Dutton R, Achana F, Antonov K: Estimating the budget impact of orphan drugs in Sweden and France 2013¿2020. Orphanet J Rare Dis 2014, 9:22. BioMed Central Full Text
• [12]GIP database. 2013.
• [13]Monitor expensive drugs: Costs of expensive and orphan drugs in hospitals [in Dutch]. The Hague, The Netherlands; 2010.
• [14]MAT turnover development on the basis of euro AIP. 2013.